Evidence File 022 · Alpha-Lipoic Acid · Method v0.14 of 4 claims researched

Alpha-Lipoic AcidALA / thioctic acid · 4 claims

One of the few supplements where the route of administration changes the answer. The evidence people cite is largely intravenous. The product people buy is oral.

4Claims scored

6Sources

600 mgStudied dose

Jul 26Reviewed

Claim 01

Reduces diabetic neuropathy symptoms, intravenous

7.2/10

Moderate·Grade A recommendation · 600 mg/day IV, 3 weeks

Pooled across trials, ALA reduced Total Symptom Score by a standardised mean difference of −2.26 (95% CI −3.12 to −1.41, p=0.00001). The intravenous subgroup drove most of it at −2.81 (95% CI −4.16 to −1.46).

The meta-analysis concluded that IV at 600 mg/day over three weeks produces a significant and clinically relevant reduction in neuropathic pain, and assigned it a grade A recommendation. A separate review of IV trials agreed on direction — improved nerve conduction velocity and symptoms — while judging the underlying evidence mainly poor quality.

The working

7Quantity

6Quality

8Consistency

9Directness

(7 × 0.25) + (6 × 0.35) + (8 × 0.25) + (9 × 0.15) = 7.2
Directness scores 9 — the Total Symptom Score measures exactly what the patient experiences. Quality is held at 6 because a separate review of the IV literature judged the evidence base mainly poor quality.

MetaMijnhout GS, et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: meta-analysis of RCTs PMID 22331979 · pooled SMD −2.26
MetaSystematic review and meta-analysis of intravenous alpha-lipoic acid in diabetic peripheral neuropathy DARE quality-assessed · evidence judged mainly poor quality

Claim 02

Reduces diabetic neuropathy symptoms, oral

6.5/10

Moderate·Statistically significant · clinical relevance unclear

The oral subgroup produced a Total Symptom Score reduction of −1.78 (95% CI −2.45 to −1.10, p=0.00001) — significant, and smaller than the intravenous figure.

The authors' own wording matters here: it is unclear whether the significant improvements seen after 3–5 weeks of oral administration at >600 mg/day are clinically relevant. A later meta-analysis of oral ALA alone covering 10 RCTs and 1,242 patients ran subgroup analyses at 600, 1200 and 1800 mg/day to try to settle the optimal dose.

This is the claim that matters commercially, because oral is what anyone can actually buy, and it is the weaker of the two.

The working

7Quantity

6Quality

7Consistency

6Directness

(7 × 0.25) + (6 × 0.35) + (7 × 0.25) + (6 × 0.15) = 6.5
Directness drops to 6. The meta-analysis authors state directly that they cannot tell whether the oral improvement is clinically relevant — a statistically real change the patient may not notice.

MetaMijnhout GS, et al. Oral subgroup analysis, SMD −1.78 PMID 22331979
MetaEffects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: meta-analysis and systematic review Nutrients 2023;15(16):3634 · 10 RCTs, 1,242 patients

Claim 03

Improves nerve conduction velocity

5.0/10

Emerging·Signal present, evidence quality poor

Intravenous ALA at 300–600 mg/day for two to four weeks was reported to significantly improve nerve conduction velocity alongside positive neuropathic symptoms. The reviewers state plainly that the evidence supporting this was mainly of poor quality, and that little effort was made to search grey literature, so relevant trials may have been missed.

Nerve conduction is a measured physiological outcome rather than a reported symptom, which makes it more objective — and also further from what a patient notices.

The working

5Quantity

3Quality

6Consistency

8Directness

(5 × 0.25) + (3 × 0.35) + (6 × 0.25) + (8 × 0.15) = 5.0
Quality scores 3 on the reviewers' own assessment of the underlying trial base.

MetaIV alpha lipoic acid 300–600 mg/day for diabetic peripheral neuropathy DARE critical abstract · conclusions judged likely reliable, evidence quality poor

Claim 04

Oral and intravenous ALA are equivalent

4.6/10

Emerging·Both routes significant · magnitudes differ

Both routes reached statistical significance in subgroup analysis: oral −1.78, intravenous −2.81. On that basis the meta-analysis described the overall result as robust across routes.

But the recommendation attached to each is not the same. Grade A went to the IV protocol. Oral got “unclear if clinically relevant.” A separate meta-analysis of acetyl-L-carnitine found effect sizes broadly similar across administration routes, so route-independence is not implausible in general — it just is not established here.

The working

4Quantity

5Quality

3Consistency

7Directness

(4 × 0.25) + (5 × 0.35) + (3 × 0.25) + (7 × 0.15) = 4.6
Scored as support for equivalence. Both subgroups reached significance, which is why this scores above 3 — but the effect sizes and the strength of recommendation differ materially.

MetaMijnhout GS, et al. Subgroup analyses by administration route PMID 22331979 · oral −1.78 vs IV −2.81

Dosage as studied

Most-studied regimen

600 mg per day, intravenous

The grade A recommendation applies to IV administration for 3 weeks. Oral trials used 600–1800 mg/day.

Intravenous: 300–600 mg/day for 2–4 weeks. This is the route carrying the strongest recommendation.
Oral: 600, 1200 or 1800 mg/day for 3–5 weeks across trials. Higher oral doses did not clearly outperform 600 mg.
Typically sold: 300–600 mg oral capsules. Nobody is selling the IV protocol to consumers.
Regulatory status: Approved in Germany for diabetic neuropathic pain and covered by health insurance. Not widely adopted elsewhere.